<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Patients with <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> are at increased risk for recurrent arterial and <z:hpo ids='HP_0004936'>venous thrombosis</z:hpo> and therefore benefit from long term <z:chebi fb="8" ids="10033">warfarin</z:chebi> therapy </plain></SENT>
<SENT sid="1" pm="."><plain>The optimal duration of <z:chebi fb="8" ids="10033">warfarin</z:chebi> therapy after a first venous thromboembolic event is however a matter of some controversy and many questions remain unanswered </plain></SENT>
<SENT sid="2" pm="."><plain>After reviewing and analysing the available evidence, we discuss some common scenarios in everyday clinical practice where treatment decisions are difficult </plain></SENT>
</text></document>